Sarcomas are a diverse and relatively rare group of malignant tumors that develop in soft tissue and bone. Soft tissue and bone sarcoma incidence rates, according to the National Cancer Institute, have increased over the past 35 years, with soft tissue sarcomas more common.
Duke Cancer Institute’s Sarcoma disease group uses a multidisciplinary, patient-centric approach to diagnose and treat both bone and soft-tissue sarcomas. Through unsurpassed clinical care, personalized treatment planning and delivery, and state-of-the-art basic scientific and clinical research, the program is the center of excellence for the treatment of sarcoma in the Southeast and beyond.
Our strengths include:
Download our Duke Cancer Patient Resource Guide.
With a goal to fast-track the design and approval of clinical trials, our scientists are leading the way in the research of sarcoma and studying the cancer in children as well as adults. We aim to have a clinical trial option for every patient.
We are investigating, in the lab, possible agents to fight rhabdomyosarcoma and other sarcoma subtypes.
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More